Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 19, 2018, Pages 4969-4974

  Qin, Xian Yang ^a,j   Suzuki, Harukazu ^a,j   Honda, Masao ^b   Okada, Hikari ^b   Kaneko, Shuichi ^b   Inoue, Ikuyo ^a,j   Ebisui, Etsuko ^a,j   Hashimoto, Kosuke ^a,j   Carninci, Piero ^a,j   Kanki, Keita ^c   Tatsukawa, Hideki ^d   Ishibashi, Naoto ^e   Masaki, Takahiro ^f   Matsuura, Tomokazu ^f   Kagechika, Hiroyuki ^g   Toriguchi, Kan ^h   Hatano, Etsuro ^h   Shirakami, Yohei ⁱ   Shiota, Goshi ^c   Shimizu, Masahito ⁱ   Moriwaki, Hisataka ⁱ   Kojima, Soichi ^a,j   more..

^a RIKEN   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e KOWA COMPANY LTD   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ GIFU UNIVERSITY   (Japan)

^j Institute of Physical and Chemical Research   (Japan)

more..

Author keywords

Acyclic retinoid; Cancer stem cell; Hepatocellular carcinoma; MYCN; Transcriptome

Indexed keywords

ACYCLIC RETINOID; ANTINEOPLASTIC AGENT; BETA CATENIN; CASPASE 8; N MYC PROTO ONCOGENE PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; WNT PROTEIN; 3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; EPCAM PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE; MYCN PROTEIN, HUMAN; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; CELL SUBPOPULATION; COHORT ANALYSIS; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVATION; FLOW CYTOMETRY; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; WNT SIGNALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EPITHELIAL CELL ADHESION MOLECULE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; N-MYC PROTO-ONCOGENE PROTEIN; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS; TRETINOIN; WNT SIGNALING PATHWAY;

EID: 85046635283     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1802279115     Document Type: Article

References (50)

1. Venook AP, Papandreou C, Furuse J, de Guevara LL (2010) The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 15:5–13.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529–538.
3. Yoshimoto S, et al. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101, and erratum (2014) 506:396.
4. Kang TW, et al. (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547–551.
5. Ma C, et al. (2016) NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531:253–257.
6. Zeng H, et al. (2015) Cancer survival in China, 2003-2005: A population-based study. Int J Cancer 136:1921–1930.
7. Shimizu M, Shirakami Y, Imai K, Takai K, Moriwaki H (2012) Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis. J Carcinog 11:11.
8. Mishra L, et al. (2009) Liver stem cells and hepatocellular carcinoma. Hepatology 49: 318–329.
9. Yamashita T, et al. (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461.
10. Yamashita T, et al. (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012–1024.
11. Ma S, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542–2556.
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646–674.
13. Moriwaki H, et al. (1997) Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 3:727–731.
14. Muto Y, et al.; Hepatoma Prevention Study Group (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334:1561–1567.
15. Sano T, et al. (2005) Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 51:197–206.
16. Matsushima-Nishiwaki R, et al. (2003) Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 24:1353–1359.
17. Qin XY, et al. (2016) Metabolome analyses uncovered a novel inhibitory effect of acyclic retinoid on aberrant lipogenesis in a mouse diethylnitrosamine-induced hepatic tumorigenesis model. Cancer Prev Res (Phila) 9:205–214.
18. Takahashi K, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872.
19. Dang CV (2012) MYC on the path to cancer. Cell 149:22–35.
20. Qin XY, et al.; FANTOM consortium (2017) Transcriptome analysis uncovers a growth-promoting activity of Orosomucoid-1 on hepatocytes. EBioMedicine 24:257–266.
21. Dauch D, et al. (2016) A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med 22:744–753.
22. Brodeur GM (2003) Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203–216.
23. Tatsukawa H, et al. (2011) Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 10:4.
24. Qin XY, Fujii S, Shimizu A, Kagechika H, Kojima S (2015) Carboxylic derivatives of vitamin K2 inhibit hepatocellular carcinoma cell growth through caspase/transglutaminase-related signaling pathways. J Nutr Sci Vitaminol (Tokyo) 61:285–290.
25. Matsuzawa N, et al. (2007) Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392–1403.
26. Shimizu M, et al. (2011) Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice. Cancer Prev Res (Phila) 4:128–136.
27. Teitz T, et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529–535.
28. Sung WK, et al. (2012) Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44:765–769.
29. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive mod-elling of anticancer drug sensitivity. Nature 483:603–607.
30. Zheng YW, et al. (2014) The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. Stem Cells Dev 23:2237–2249.
31. Lavi O, Greene JM, Levy D, Gottesman MM (2013) The role of cell density and in-tratumoral heterogeneity in multidrug resistance. Cancer Res 73:7168–7175.
32. Cerec V, et al. (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957–967.
33. Okita K, et al.; Peretinoin Study Group (2015) Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol 50:667–674.
34. Honda M, et al. (2013) Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer 13:191.
35. Hashimoto K, et al. (2015) CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res 25:1812–1824.
36. Kanki K, et al. (2013) Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells. J Hepatol 59:1037–1044.
37. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404.
38. Poon RT, et al. (2000) Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500–507.
39. Imamura H, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207.
40. Poon RT (2011) Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology 54:757–759.
41. Okita K, et al.; Peretinoin Study Group (2015) Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: A randomized double-blind placebo-controlled study. J Gastroenterol 50:191–202.
42. Sokol SY (2011) Maintaining embryonic stem cell pluripotency with Wnt signaling. Development 138:4341–4350.
43. Valent P, et al. (2012) Cancer stem cell definitions and terminology: The devil is in the details. Nat Rev Cancer 12:767–775.
44. Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338.
45. Carroll PA, et al. (2015) Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell 27:271–285.
46. Shiraki T, et al. (2003) Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc Natl Acad Sci USA 100:15776–15781.
47. Gustafson WC, et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414–427.
48. Shrestha R, et al. (2015) Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis 6:e2002.
49. Tatsukawa H, et al. (2009) Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 136:1783–1795.e10.
50. Kramps C, Strieder V, Sapetschnig A, Suske G, Lutz W (2004) E2F and Sp1/Sp3 syner-gize but are not sufficient to activate the MYCN gene in neuroblastomas. J Biol Chem 279:5110–5117.